|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:acquired
|
$375 million funding
|
|
gptkbp:acquisition
|
gptkb:Kite_Pharma
|
|
gptkbp:allies
|
gptkb:Genentech
|
|
gptkbp:awarded_for
|
gptkb:European_Inventor_Award
gptkb:European_Inventor_Award_(2021)
|
|
gptkbp:awards
|
gptkb:European_Inventor_Award_(2021)
gptkb:German_Business_Innovation_Award_(2021)
gptkb:German_Innovation_Award_(2021)
gptkb:Global_Health_Award_(2021)
gptkb:TIME_100_Most_Influential_People_(2021)
|
|
gptkbp:ceo
|
gptkb:Özlem_Türeci
gptkb:Uğur_Şahin
|
|
gptkbp:clinical_trial
|
gptkb:COVID-19_vaccine_booster
Phase 1
Phase 2
Phase 3
cancer vaccines
malaria vaccine
HIV vaccine
Zika virus vaccine
tuberculosis vaccine
|
|
gptkbp:collaborates_with
|
gptkb:Moderna
|
|
gptkbp:collaboration
|
gptkb:Moderna
gptkb:Fosun_Pharma
|
|
gptkbp:collaborations
|
gptkb:Harvard_University
gptkb:Johns_Hopkins_University
gptkb:University_of_Pennsylvania
|
|
gptkbp:developed_by
|
gptkb:BNT162b2
|
|
gptkbp:develops
|
m RNA-based vaccines
|
|
gptkbp:employees
|
over 1,000
over 1,500
|
|
gptkbp:established_in
|
gptkb:2008
|
|
gptkbp:focus_area
|
m RNA technology
|
|
gptkbp:focuses_on
|
gptkb:immunotherapy
|
|
gptkbp:founded
|
gptkb:2008
|
|
gptkbp:founded_by
|
gptkb:Özlem_Türeci
gptkb:Uğur_Şahin
|
|
gptkbp:founded_in
|
gptkb:2008
|
|
gptkbp:founder
|
gptkb:Özlem_Türeci
gptkb:Uğur_Şahin
|
|
gptkbp:global_presence
|
over 100 countries
|
|
gptkbp:grants
|
gptkb:German_government
|
|
gptkbp:has_a_focus_on
|
personalized medicine
vaccine development
therapeutic vaccines
cell and gene therapies
|
|
gptkbp:has_intellectual_property_in
|
m RNA technology
|
|
gptkbp:has_part
|
gptkb:Bio_NTech_SE
|
|
gptkbp:has_partnerships_with
|
gptkb:Merck
gptkb:GSK
gptkb:Astra_Zeneca
gptkb:Sanofi
gptkb:Cure_Vac
gptkb:Novartis
gptkb:Fosun_Pharma
|
|
gptkbp:has_pipeline_for
|
therapeutics
|
|
gptkbp:has_product
|
gptkb:BNT162b2
gptkb:BNT162b1
gptkb:BNT162b10
gptkb:BNT162b11
gptkb:BNT162b13
gptkb:BNT162b14
gptkb:BNT162b15
gptkb:BNT162b16
gptkb:BNT162b17
gptkb:BNT162b18
gptkb:BNT162b20
gptkb:BNT162b21
gptkb:BNT162b3
gptkb:BNT162b4
gptkb:BNT162b6
gptkb:BNT162b7
gptkb:BNT162b8
gptkb:BNT162a1
gptkb:BNT162c2
gptkb:Comirnaty
BNT111
influenza vaccine
respiratory syncytial virus vaccine
BNT162b12
BNT162b19
BNT162b22
BNT162b23
BNT162b24
BNT162b25
BNT162b26
BNT162b27
BNT162b28
BNT162b29
BNT162b30
BNT162b31
BNT162b32
BNT162b33
BNT162b34
BNT162b35
BNT162b36
BNT162b37
BNT162b38
BNT162b39
BNT162b40
BNT162b41
BNT162b42
BNT162b43
BNT162b44
BNT162b45
BNT162b46
BNT162b47
BNT162b48
BNT162b49
BNT162b5
BNT162b50
BNT162b9
BNT122
|
|
gptkbp:has_product_line
|
cancer immunotherapies
|
|
gptkbp:has_public_offering
|
gptkb:2020
|
|
gptkbp:has_research_center
|
gptkb:Berlin,_Germany
gptkb:Cambridge,_Massachusetts
|
|
gptkbp:has_research_focus
|
gptkb:cancer_treatment
rare diseases
autoimmune diseases
infectious diseases
|
|
gptkbp:has_technology_platform_for
|
lipid nanoparticles
m RNA technology
|
|
gptkbp:has_technology_transfer_agreement_with
|
gptkb:Pfizer
|
|
gptkbp:headquarters
|
gptkb:Mainz,_Germany
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Bio NTech
|
|
gptkbp:industry
|
gptkb:pharmaceuticals
|
|
gptkbp:investment
|
gptkb:Bill_&_Melinda_Gates_Foundation
gptkb:Soft_Bank
|
|
gptkbp:is_vulnerable_to
|
gptkb:virus
gptkb:HIV
gptkb:COVID-19
gptkb:Comirnaty
malaria
tuberculosis
|
|
gptkbp:known_for
|
gptkb:vaccine
m RNA vaccine development
|
|
gptkbp:market_cap
|
$20 billion (2021)
|
|
gptkbp:notable_products
|
gptkb:BNT162b2
|
|
gptkbp:partnership
|
gptkb:Genentech
gptkb:Sanofi
gptkb:Pfizer
gptkb:Cure_Vac
|
|
gptkbp:philanthropy
|
education initiatives
community health programs
scientific research grants
support for research funding
COVID-19 vaccine access initiatives
|
|
gptkbp:publicly_traded
|
gptkb:NASDAQ
|
|
gptkbp:research_areas
|
cancer immunotherapy
|
|
gptkbp:research_institutes
|
gptkb:Harvard_University
gptkb:Johns_Hopkins_University
gptkb:University_of_Mainz
|
|
gptkbp:revenue
|
$18.9 billion (2021)
$482 million (2020)
|
|
gptkbp:stock_symbol
|
gptkb:BNTX
|
|
gptkbp:subsidiary
|
gptkb:Bio_NTech_RNA_Pharmaceuticals
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:vaccine_type
|
gptkb:vaccine
|
|
gptkbp:bfsParent
|
gptkb:Pfizer
gptkb:Pfizer_Inc.
|
|
gptkbp:bfsLayer
|
4
|